GLP-1 medications such as Ozempic, Wegovy, and Zepbound have become widely used for treating obesity, type 2 diabetes, and other chronic health conditions. But a recent study presented at the 2026 American Academy of Orthopaedic Surgeons annual meeting brought new attention to a possible downside: a link between GLP-1 use and a higher risk of osteoporosis, osteomalacia, and gout. The research, which has not yet been peer-reviewed, reviewed five years of medical records from nearly 147,000 adults with type 2 diabetes and obesity and reported a “significantly increased” risk of those conditions among GLP-1 users.
Even so, experts say the findings should be interpreted carefully. According to Marci Laudenslager, MD, of The Johns Hopkins Healthful Eating, Activity & Weight Program, there is currently no strong scientific evidence showing that GLP-1 drugs directly cause osteoporosis, osteomalacia, or gout. Because the study was observational, it can show an association but not prove cause and effect. It also relied on medical records that may not reflect whether people actually took the medication, since cost, shortages, insurance problems, and side effects can all interrupt use. In addition, the analysis did not fully account for exercise, nutrition, alcohol use, family history, steroid use, cancer, or endocrine conditions, all of which can influence bone health.
Experts say there is still a broader question worth watching: bone density can decline when people lose weight quickly, no matter how that weight loss happens. Kelyssa Hall, an exercise physiologist and certified strength and conditioning specialist at Hospital for Special Surgery, said less body weight means less mechanical load on the skeleton, and bones respond to load by staying stronger. Over time, that reduced loading may contribute to lower bone density. Dr. Laudenslager noted that this pattern is not unique to GLP-1s; significant weight loss through lifestyle changes, medication, or surgery can all affect bone metabolism. The takeaway, according to the report, is that more research is needed to understand how GLP-1 use and weight loss may interact with long-term bone health.
For now, the study has added to a growing conversation about how these medications affect the body beyond weight loss and blood sugar control. Experts emphasized that the current evidence does not prove the drugs themselves are damaging bones, but it does suggest bone health deserves more attention as GLP-1 use continues to expand.
Source: self.com
